This is why ERCC1 has been the most investigated potential biomarker of therapeutic response at the genomic level (analysis of single-nucleotide polymorphisms), at the transcriptional level (reverse transcriptase PCR) and at the protein level (immunohistochemistry- IHC) in different tumor types, in retrospective and prospective studies [7,8]. Here, ERCC1 is linked to neoplasm.